CMPMedica, iSOFT sign global contract for drug information decision-support tools

CMPMedica, a division of United Business Media Limited, and healthcare IT sysytems supplier iSOFT, have signed a worldwide agreement to supply iSOFT with comprehensive evidence-based drug information. CMPMedica’s information solution will power iSOFT’s suite of decision-support tools. These tools enable healthcare professionals to make better informed decisions at the point of care and thus improve patient outcomes. CMPMedica has provided iSOFT with drug information systems since the 1960s the two companies have worked together to develop their respective businesses in Australia and Asia. Both companies are looking to expand their relationship into new territories around the world as demand for evidence-based decision support tools continues to grow. Henry Elkington, CEO of CMPMedica said: “The award of this contract demonstrates that we are addressing the needs of one of the most dynamic multi-national healthcare solution providers. By providing trusted local data with best-in-class decision support tools we are enabling solutions that will be recognised and welcomed by clinicians. In addition, by delivering data through a common interface we can speed up and simplify deployment for the solution provider.” Dr Michael Dahlweid, iSOFT’s Chief Medical Officer said: “The agreement with CMPMedica will provide improved and real-time access to CMPMedica’s sophisticated knowledgebases. When interacting with iSOFT products, these decision-support tools will provide the capacity to alert clinicians to interactions between medicines, food, health conditions and patient allergies and more, making patient safety the priority in a world of increasing drug complexity.” “This new service will strengthen the quality of the drug content available within iSOFT products giving our customers ready access to the very latest drug and allergy information ensuring that prescribing clinicians have up-to-date and fully integrated drug information to enhance patient treatment and safety.”

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video